SAMHSA stats on integrated care
- Sober Soldiers summarized research showing integrated treatment improves recovery versus separate care for co‑occurring disorders. - They highlighted that medication‑assisted treatment (MAT) reduces opioid mortality by about 50% and that 90+ days in treatment recalibrates brain pathways. - The post framed these findings as practical clinician evidence for integrated care and sustained engagement (x.com).
Integrated care treats mental illness and substance use disorder at the same time, and SAMHSA says that approach produces better health outcomes than treating each problem separately. (samhsa.gov) SAMHSA says people who show up for either kind of help should be screened for both conditions under a “no wrong door” model, because co-occurring disorders complicate diagnosis and raise the odds of hospitalization. (samhsa.gov) The agency describes three ways to organize that care — coordinated, co-located, and fully integrated — and says integrated treatment can reduce substance use, improve psychiatric symptoms, cut hospitalizations, and increase housing stability. (samhsa.gov) SAMHSA’s 2020 advisory on co-occurring disorders said 48.6% of U.S. adults with those disorders received either specialty substance-use treatment or mental health services in the prior year, while 7.8% received both. (samhsa.gov) That gap is one reason integrated care keeps resurfacing in federal guidance: the same advisory tells providers to build one comprehensive, individualized plan that treats both disorders together. (samhsa.gov) Medication treatment is one of the clearest examples. SAMHSA says medications for substance use disorders improve survival and help people stay in treatment and recovery services longer. (samhsa.gov) National Institutes of Health-backed research found methadone cut opioid-overdose death risk by 59% and buprenorphine by 38% among adults in Massachusetts after a nonfatal overdose, which is the basis for the shorthand claim that treatment reduces mortality by about half. (nih.gov) NIDA, the National Institute on Drug Abuse, says medications for opioid use disorder reduce overdose deaths, yet fewer than 1 in 5 people with opioid use disorder receive them. A separate NIDA clinical resource page put the figure at 22% in 2021. (nih.gov 1) (nih.gov 2) The “90 days” benchmark is usually about retention, not a federal claim that the brain is “recalibrated” on a set schedule. NIDA said a 2023 Medicaid study found 90-day buprenorphine retention was higher with telehealth starts — 48% versus 44% in Kentucky and 32% versus 28% in Ohio. (nih.gov) SAMHSA’s latest annual National Survey on Drug Use and Health, released July 28, 2025 with 2024 data from nearly 70,000 respondents, is the federal baseline for how often mental illness, substance use, and treatment overlap in the U.S. (samhsa.gov) The thread running through the federal guidance is simple: screen for both disorders, treat both disorders, and keep people engaged long enough for the treatment to work. (samhsa.gov)
